Published in Adv Med on September 07, 2014
Cell Type-Specific Effects of Mutant DISC1: A Proteomics Study. Mol Neuropsychiatry (2016) 0.75
An Improved 2-Dimensional Gel Electrophoresis Method for Resolving Human Erythrocyte Membrane Proteins. Proteomics Insights (2017) 0.75
The impact of growth hormone on proteomic profiles: a review of mouse and adult human studies. Clin Proteomics (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Molecular portraits of human breast tumours. Nature (2000) 94.14
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics (2002) 30.58
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
The cancer genome. Nature (2009) 23.13
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol (1999) 21.92
Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics (2004) 19.05
Electrospray ionization for mass spectrometry of large biomolecules. Science (1989) 16.50
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics (2010) 13.35
Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol (2006) 10.14
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem (1988) 9.56
Lessons from the cancer genome. Cell (2013) 8.12
Mass spectrometry and protein analysis. Science (2006) 8.05
Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem (1997) 6.99
Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2007) 6.96
Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem (2003) 6.63
Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics (2012) 5.95
Next-generation genomics: an integrative approach. Nat Rev Genet (2010) 5.88
Bring on the biomarkers. Nature (2011) 5.77
Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res (2004) 5.57
Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol (2011) 5.48
SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell (2008) 5.02
Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods (2012) 4.93
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 4.40
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res (2006) 4.28
A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat Methods (2009) 4.23
Mining the plasma proteome for cancer biomarkers. Nature (2008) 4.10
IDPicker 2.0: Improved protein assembly with high discrimination peptide identification filtering. J Proteome Res (2009) 3.72
Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics (2009) 3.65
Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem (2003) 3.63
iTRAQ underestimation in simple and complex mixtures: "the good, the bad and the ugly". J Proteome Res (2009) 3.61
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem (2008) 3.23
A database of mass spectrometric assays for the yeast proteome. Nat Methods (2008) 3.19
Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem (2011) 3.19
Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics (2004) 3.14
mProphet: automated data processing and statistical validation for large-scale SRM experiments. Nat Methods (2011) 3.10
Addressing accuracy and precision issues in iTRAQ quantitation. Mol Cell Proteomics (2010) 3.10
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics (2012) 3.05
Label-free, normalized quantification of complex mass spectrometry data for proteomic analysis. Nat Biotechnol (2009) 3.01
Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods (2010) 2.95
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
MRMer, an interactive open source and cross-platform system for data extraction and visualization of multiple reaction monitoring experiments. Mol Cell Proteomics (2008) 2.89
A human proteome detection and quantitation project. Mol Cell Proteomics (2009) 2.80
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem (2009) 2.77
Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol (2009) 2.70
Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem (2006) 2.55
Next-generation high-density self-assembling functional protein arrays. Nat Methods (2008) 2.46
Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2009) 2.42
Mass spectrometry from miniaturized arrays for full comparative DNA analysis. Nat Med (1997) 2.41
An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics (2009) 2.40
Next-generation proteomics: towards an integrative view of proteome dynamics. Nat Rev Genet (2012) 2.39
Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance. Mol Cell Proteomics (2009) 2.39
A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 2.39
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics (2014) 2.37
Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 2.32
Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst (2010) 2.29
Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst (2004) 2.28
Imaging mass spectrometry of proteins and peptides: 3D volume reconstruction. Nat Methods (2008) 2.24
Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res (2009) 2.20
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. Clin Chem (2009) 2.14
Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif) (2013) 2.11
Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin Chem (2010) 2.11
Performance metrics for liquid chromatography-tandem mass spectrometry systems in proteomics analyses. Mol Cell Proteomics (2009) 2.09
Translation control: bridging the gap between genomics and proteomics? Trends Biochem Sci (2001) 2.08
Somatic alterations in the human cancer genome. Cancer Cell (2004) 1.97
The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem (2006) 1.95
Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal Chem (2004) 1.94
Current trends in quantitative proteomics. J Mass Spectrom (2009) 1.82
Comprehensive label-free method for the relative quantification of proteins from biological samples. J Proteome Res (2005) 1.81
High-throughput sequencing for biology and medicine. Mol Syst Biol (2013) 1.75
Protease-catalyzed incorporation of 18O into peptide fragments and its application for protein sequencing by electrospray and matrix-assisted laser desorption/ionization mass spectrometry. Electrophoresis (1996) 1.71
Current developments in SELDI affinity technology. Mass Spectrom Rev (2003) 1.67
Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques. Bioinformatics (2006) 1.65
Quantitative proteomic analysis of single pancreatic islets. Proc Natl Acad Sci U S A (2009) 1.62
Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. Nat Protoc (2006) 1.61
Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol Cell Proteomics (2008) 1.58
Spatial and temporal alterations of phospholipids determined by mass spectrometry during mouse embryo implantation. J Lipid Res (2009) 1.58
Western blots versus selected reaction monitoring assays: time to turn the tables? Mol Cell Proteomics (2013) 1.57
Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A (2011) 1.56
HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat Methods (2013) 1.55
Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods (2013) 1.54
Isotope dilution strategies for absolute quantitative proteomics. J Proteomics (2009) 1.54
Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci U S A (2012) 1.52
Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med (2006) 1.52
Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol Cell Proteomics (2008) 1.51
SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics (2009) 1.50
Proteogenomics. Proteomics (2011) 1.48
Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies. J Mass Spectrom (2003) 1.47
The quantitative proteomes of human-induced pluripotent stem cells and embryonic stem cells. Mol Syst Biol (2011) 1.44